Article Information
History
- January 30, 2021.
Article Versions
- Version 1 (January 29, 2021 - 03:30).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Sandra Lopez-Leon, MD, PhD1,
- Talia Wegman-Ostrosky, MD, PhD2,
- Carol Perelman, BSc3,
- Rosalinda Sepulveda, MD PhD4,
- Paulina A Rebolledo, MD, MSc5,6,
- Angelica Cuapio, MD, Dr. Med7 and
- Sonia Villapol, PhD8,9,*
- 1Drug Development, Novartis Pharmaceuticals, New Jersey, USA
- 2Instituto Nacional de Cancerología, Subdirección de Investigación básica, Ciudad de México, México
- 3National Autonomous University of Mexico, SOMEDICyT, RedMPC, México
- 4Harvard T.H. Chan School of Public Health Boston, Massachusetts, USA
- 5Divison of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
- 6Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
- 7Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden
- 8Department of Neurosurgery, Center for Neuroregeneration, Houston Methodist Research Institute, Houston, Texas, USA
- 9Department of Neuroscience in Neurological Surgery, Weill Cornell Medical College, New York, USA
- ↵*Correspondence to Sonia Villapol, Ph.D., 6670 Bertnet Avenue, Houston, TX, 77030. svillapol{at}houstonmethodist.org.
Posted January 30, 2021.
More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis
